Half Year 2025 Polarean Imaging PLC Earnings Call Transcript
Key Points
- Polarean Imaging PLC (FRA:8ZF) has an FDA-approved Xenon MRI platform, which is the only non-invasive, radiation-free technology that provides a complete picture of lung function.
- The company has expanded its market reach with pediatric approval, broadening access to over 1 million more potential patients.
- Polarean Imaging PLC has a strong scientific and clinical validation with nearly 1,000 publications and over 200 clinical studies.
- The company has secured a significant order from the NIH, indicating growing interest and validation of their technology.
- Polarean Imaging PLC has a robust pipeline with a 650% increase in quotes year over year, indicating strong commercial momentum.
- First half revenue was disappointing, with no new systems closed, leading to a downward revision of revenue guidance for 2025.
- The company faces market headwinds due to NIH funding cuts and new Medicaid reductions, impacting hospital budgets and slowing capital purchases.
- There is uncertainty in the market, expected to continue into 2026, as academic centers reassess and reset their budgets.
- Polarean Imaging PLC needs to secure additional financing to fund operations beyond Q2 2026 and to start the gas exchange trial.
- The company is experiencing challenges in the US market due to policy changes and economic pressures, affecting capital equipment sales.
Good afternoon and welcome to the Polarean Imaging PLC investor presentation. (Operator Instructions)
I'd now like to hand you over to Christopher von Jako, CEO. Good afternoon, sir.
Thank you so much. I appreciate it. So hello, as mentioned, my name is Chris von Jako. I'm the CEO of Polarean, and I'm joined today by our CFO, Chuck Osborne. So thank you for taking the time to be with us.
I'll begin with an overview and some additional context of the RNS we released this morning. And after that, I'll walk through an updated presentation, both as a refresher for those familiar with Polarean, and as an introduction for any new to the story. Finally, Chuck and I will take a number of questions at the end of the presentation.
So before I begin, just as a reminder, these are the normal disclaimers. We are revolutionizing pulmonary medicine with our FDA-approved Xenon MRI platform. It is the only non-invasive, radiation-free technology that shows the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
